Stanford Cancer Institute
Developmental Therapeutics

Solid Tumors

VAR0105
Phase I/II
ABT-165
ABT-165, a Dual Variable Domain Immunoglobulin in Advanced Solid Tumors
PI: Kummar Pending

VAR0176
Phase I
Nivolumab +/- Ipilimumab According to % of Tumoral CD8 Cells in Advanced Metastatic Cancer
PI: Kummar Pending

VAR0175
Phase I Intratumoral Injection of SD-101 +/- BMS-986178 in Advanced Solid Malignancies
PI: Kummar Pending

VAR0172
Phase Ib Camidanlumab Tesirine (ADCT-301) in Selected Advanced Solid Tumors
PI: Kummar Pending

VAR0171
Phase III
TAS0728 Oral Covalent Binding Inhibitor of HER2 in SolidTumors w/ HER2/HER3 Abnormalities
PI: Kummar Tahoe Oncology

VAR0173
Phase Ib NCMGA600012 in Combination w/ Other Therapies in Patients With Advanced Solid Tumors
PI: Kummar Pending

VAR0143
Phase I/II
ICOS Agonist mAb JTX-2011 +/- Nivolumab in Advanced Refractory Solid Tumor Malignancies
PI: Kummar Jounce Therapeutics

VAR0148
Phase I
MCD009 in Unresectable/Metastatic B7-H3 Expressing Neoplasms
PI: Kummar MacroGenics

VAR0152
Phase II/III of EDO-S101 in Advanced Solid Tumors
PI: Kummar Pending

NTRK Fusion-Positive Tumors

IDH 1/2 Mutant Tumors

VAR0154
Phase I/II
TRK Inhibitor LOXO-195 in Adult and Pediatric Previously Treated NTRK Fusion Cancers
PI: Kummar Loxo Oncology

VAR0136
Phase II
Basket Study of the Oral TRK Inhibitor LOXO-101 in NTRK Fusion-Positive Tumors
PI: Kummar Loxo Oncology

VAR0167
Phase II PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
PI: Bui Pending

KEY
Pending
Open for Enrollment
Observational Study
Enrollment on Hold
Optional Path
Trial Posting
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu